Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2009-10-26 Annual Report
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Annual Report to shareholders 60 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2009' and contains detailed sections typical of an annual report, including a Chairman's Letter, Operations Report, Directors' Report, Remuneration Report, Auditor's Independence Declaration, Independent Audit Report, Income Statement, Balance Sheet, Cash Flow Statement, Statement of Changes in Equity, Notes to the Financial Statements, Directors' Declaration, Corporate Governance Statement, and Shareholder Information. The content includes comprehensive financial and operational information for the fiscal year 2009, with no indication that it is merely an announcement or a summary. The length of the document (15,000 characters) and the presence of detailed financial statements and audit reports confirm it is a full annual report. Therefore, the appropriate classification is Annual Report (10-K). FY 2009
2009-10-26 English
Notice of Annual General Meeting/Proxy Form 6 pages ?Kb
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' for Imugene Limited, detailing the date, time, and location of the AGM. It includes the agenda items such as receiving the financial report, the remuneration report, and the re-election of a director. It also contains a proxy form for shareholders to vote. The document references the Annual Report and financial statements but does not contain the financial statements or detailed financial data itself. It is a notice and explanatory statement for the AGM, not the actual Annual Report or financial report. Therefore, it fits the category of AGM Information (AGM-R). The document length is substantial but the content is clearly a meeting notice and related materials, not a full report or transcript.
2009-10-26 English
Appendix 4E and 2009 Financial Report 53 pages ?Kb
Annual Report Classification · 100% confidence The document is an ASX announcement dated 27 August 2009 titled '2009 Financial Report' for Imugene Limited for the year ended 30 June 2009. It includes an Appendix 4E preliminary final report and references an attached audited Annual Financial Report. The content includes detailed financial results, directors' report, auditor's report, financial statements, and notes, all typical components of a full annual report. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement or summary. The presence of audited financial statements and comprehensive directors' commentary confirms this is the official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K equivalent). FY 2009
2009-08-27 English
Change of Director`s Interest Notices 4 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and contains detailed disclosures of changes in securities holdings by company directors, including dates, number of shares acquired or disposed, and consideration values. It references ASX listing rules and the Corporations Act, indicating it is a regulatory filing related to insider trading or director share transactions. The content is focused on personal share transactions by company directors, which matches the definition of Director's Dealing filings. The document length is over 6000 characters and contains substantive data on director share transactions, not just an announcement or certification. Therefore, the appropriate classification is Director's Dealing (DIRS).
2009-08-18 English
Response to ASX Query 3 pages ?Kb
Regulatory Filings Classification · 100% confidence The document is a letter from Imugene Limited responding to a query from the Australian Securities Exchange (ASX) regarding unusual trading activity in the company's securities. The letter addresses compliance with listing rules, specifically listing rule 3.1, and confirms that the company is not aware of any undisclosed information that could explain the trading activity. The document is a regulatory response to a market query rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or detailed financial data. It is also not a report publication announcement but a regulatory filing responding to a compliance inquiry. Therefore, the appropriate classification is Regulatory Filings (RNS).
2009-08-18 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares held before and after the change, nature of the interest, and transaction details such as on-market trade and consideration amount. This is a report of personal share transactions by a company director. The document length is 3178 characters, which is consistent with a detailed director's dealing notice rather than a brief announcement or other report type. Therefore, the document fits the definition of Director's Dealing (DIRS).
2009-08-13 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.